id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-312801-tllj77up	Giovannoni, Gavin	The COVID-19 pandemic and the use of MS disease-modifying therapies	2020-03-27		.txt	text/plain	3053	167	47	It is essential to consider the potential risk of morbidity and possible mortality for each MS patient, who may be infected with SARS-CoV-2 and develops COVID-19. Assuming that antiviral responses are driven mainly by T-cells, in particular CD8+ cytotoxic T-lymphocytes, and natural-killer cells and less so, at least initially, by B-cells, allows one to construct a hierarchy of immunosuppression of DMTs. The highest risk are the immune reconstitution therapies during the depletion phase of the treatment, i.e. haematopoietic stem cell transplantation (HSCT), alemtuzumab (Lemtrada), mitoxantrone (Novantrone) and cladribine (Mavenclad). This is why patients on S1P modulators should be at relatively low risk of complications from COVID-19 infection and why it may be safe to continue these treatments during the epidemic. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies	./cache/cord-312801-tllj77up.txt	./txt/cord-312801-tllj77up.txt